Drug Trial Radar · NCT05847179
Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin in Werner Syndrome
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
5
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- PRG Science & Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, open-label study to A Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin for the Treatment of Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome. There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year.
Conditions
- Werner Syndrome
Interventions
ProgerininDrug
This is a Phase 2, open-label study to evaluate the safety and Tolerability of Progerinin for the treatment of BMD Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome. . There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year. This study will have three phases: Screening Phase, Treatment Phase, and Follow-Up Phase.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)Time frame: Baseline to Week 56 (including 4-week follow-up)
- Incidence of Treatment-Related Adverse EventsTime frame: Baseline to Week 56 (including 4-week follow-up)
- Incidence of Serious Adverse Events (SAEs)Time frame: Baseline to Week 56 (including 4-week follow-up)
- Incidence of TEAEs and SAEs leading to discontinuation of study medicationTime frame: Baseline to Week 56 (including 4-week follow-up)
- Changes in Blood Chemistry from BaselineTime frame: Baseline to Week 56 (including 4-week follow-up)
- Changes in Hematology from BaselineTime frame: Baseline to Week 56 (including 4-week follow-up)
- Changes in Urinalysis Results from BaselineTime frame: Baseline to Week 56 (including 4-week follow-up)
- Changes in Height (cm) from BaselineTime frame: Baseline to Week 56 (including 4-week follow-up)
- Changes in Weight (kg) from baselineTime frame: Baseline to Week 56 (including 4-week follow-up)
- Changes in Temperature (°C) from baselineTime frame: Baseline to Week 56 (including 4-week follow-up)
- Changes in Pulse Rate (beats per minute) from baselineTime frame: Baseline to Week 56 (including 4-week follow-up)
- Changes in Respiratory Rate (breaths per minute) from baselineTime frame: Baseline to Week 56 (including 4-week follow-up)
- Changes in Systolic Blood pressure (mmHg) from baselineTime frame: Baseline to Week 56 (including 4-week follow-up)
- Changes in Diastolic Blood pressure (mmHg) from baselineTime frame: Baseline to Week 56 (including 4-week follow-up)
- Changes in Physical Examination findings from baselineTime frame: Baseline to Week 56 (including 4-week follow-up)
- Change in ECG Ventricular Rate (beats per minute) from baselineTime frame: Baseline to Week 56 (including 4-week follow-up)
- Change in ECG PR interval (msec) from baselineTime frame: Baseline to Week 56 (including 4-week follow-up)
- Change in ECG QRS interval (msec) from baselineTime frame: Baseline to Week 56 (including 4-week follow-up)
- Change in ECG QT interval (msec) from baselineTime frame: Baseline to Week 56 (including 4-week follow-up)
- Change in ECG QTc interval (msec) from baselineTime frame: Baseline to Week 56 (including 4-week follow-up)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Michigan
Ann Arbor, Michigan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.